ArticleJournal of the American Society for Mass Spectrometry2018
MALDI Mass Spectrometry Imaging for Evaluation of Therapeutics in Colorectal Tumor Organoids.
Article in Journal of the American Society for Mass Spectrometry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 83 citations in OpenAlex.
- Mapping the kidney distribution of Huangkui capsule-derived components in diabetic nephropathy treatment: a mass spectrometry imaging and metabolomics approach nominates quercetin and its conjugates as bioactive candidates.Analytical and bioanalytical chemistry · 2026Article
- A photocleavable peptidic Ru(ii) mass-tag enabling targeted DESI and MALDI mass spectrometry imaging in cancer tissues.Chemical science · 2026Article
- Re-Thinking Pharmacokinetics in Ovarian Cancer: What Do Organoids Add?International journal of molecular sciences · 2026Review
- Matrix-Assisted Laser Desorption/Ionization Imaging Mass Spectrometry.Nature reviews. Methods primers · 2026Article
- Review
- A Practical Guide to Developing and Troubleshooting Patient-Derived "Mini-Gut" Colorectal Organoids for Clinical Research.Methods and protocols · 2025Article
- Seeing between the lines: matrix-assisted laser desorption/ionization mass spectrometry imaging advances for microbial interactions.Current opinion in microbiology · 2025Review
- Direct transfer of multicellular tumor spheroids grown in agarose microarrays for high-throughput mass spectrometry imaging analysis.Analytical and bioanalytical chemistry · 2025Article
- Assessing Drug Uptake and Response Differences in 2D and 3D Cellular Environments Using Stimulated Raman Scattering Microscopy.Analytical chemistry · 2024Article
- An Innovative Aggregation-Induced Emission-Based NIR Fluorescent Probe for Visualizing Carboxylesterases in Living Cells, Zebrafish, and Tumor-Bearing Mice.Molecules (Basel, Switzerland) · 2024Article
- Mass Spectrometry Imaging and Histology for the Analysis of Budding Intestinal Organoids.Analytical chemistry · 2024Article
- Integration of pan-omics technologies and three-dimensional in vitro tumor models: an approach toward drug discovery and precision medicine.Molecular cancer · 2024Review
- Quantitative mass spectrometry imaging: therapeutics & biomolecules.Chemical communications (Cambridge, England) · 2024Review
- Lipidomic Phenotyping Of Human Small Intestinal Organoids Using Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging.Analytical chemistry · 2023Article
- Targeted Energy Metabolomics Combined with Spatial Metabolomics Study on the Efficacy of Guhong Injection Against Cerebral Ischemia Reperfusion.Molecular neurobiology · 2023Article
- Exploring New Dimensions of Tumor Heterogeneity: The Application of Single Cell Analysis to Organoid-Based 3D In Vitro Models.Advanced healthcare materials · 2023Review
- Evaluating the Pharmacokinetics and Pharmacodynamics of Chemotherapeutics within a Spatial SILAC-Labeled Spheroid Model System.Analytical chemistry · 2023Article
- Full-profile pharmacokinetics, anticancer activity and toxicity of an extended release trivalent PEGylated irinotecan prodrug.Acta pharmaceutica Sinica. B · 2023Article
- Quantification of Irinotecan in Single Spheroids Using Internal Standards by MALDI Mass Spectrometry Imaging.Analytical chemistry · 2023Article
- Tissue Microarray Lipidomic Imaging Mass Spectrometry Method: Application to the Study of Alcohol-Related White Matter Neurodegeneration.Applied biosciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Patient-derived colorectal tumor organoids (CTOs) closely recapitulate the complex morphological, phenotypic, and genetic features observed in in vivo tumors. Therefore, evaluation of drug distribution and metabolism in this model system can provide valuable information to predict the clinical outcome of a therapeutic response in individual patients. In this report, we applied matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) to examine the spatial distribution of the drug irinotecan and its metabolites in CTOs from two patients. Irinotecan is a prodrug and is often prescribed as part of therapeutic regimes for patients with advanced colorectal cancer. Irinotecan shows a time-dependent and concentration-dependent permeability and metabolism in the CTOs. More interestingly, the active metabolite SN-38 does not co-localize well with the parent drug irinotecan and the inactive metabolite SN-38G. The phenotypic effect of irinotecan metabolism was also confirmed by a viability study showing significantly reduced proliferation in the drug treated CTOs. MALDI-MSI can be used to investigate various pharmaceutical compounds in CTOs derived from different patients. By analyzing multiple CTOs from a patient, this method could be used to predict patient-specific drug responses and help to improve personalized dosing regimens. Graphical Abstract ᅟ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.